$-0.49 EPS Expected for Leap Therapeutics, Inc. (LPTX); Vivus (VVUS) Has 0.57 Sentiment

Retrieved on: 2018-04-28 22:37:30

Tags for this article:

Health

Health care

Merck & Co.

Vivus

Phentermine/topiramate

Drugs

S&P 500 INDEX - CBOE

Click the tags to see associated articles and topics

$-0.49 EPS Expected for Leap Therapeutics, Inc. (LPTX); Vivus (VVUS) Has 0.57 Sentiment. View article details on hiswai:

Excerpt

<div><b>Acadian Asset Management</b> Llc owns 2.68 million shares or 0.01% of their US portfolio. Moreover, Jacobs Levy Equity Management Inc has 0.01% invested in the company for 754,600 shares. The Texas-based Next Financial Group Inc has invested 0.01% in the stock. Ajo Lp, a Pennsylvania-based ...</div>

Article found on:

View Original Article